Citations 13
Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene
Valla, Jon, Yaari, R. , Wolf, Andrew B. , Kusne, Yael , Beach, Thomas G. , Roher, Alex E., Corneveaux, Jason J., Huentelman, Matthew J. , Caselli, Richard J. , Reiman, Eric M.
Journal of Alzheimer's Disease | April 5, 2017 | Volume: 22 | Issue: 1 | Pages: 307-313
Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes
Caselli, Richard J., Dueck, Amylou C. , Locke, Dona E.C. , Sabbagh, Marwan N. , Ahern, Geoffrey L., Rapcsak, Steven Z. , Baxter, Leslie C. , Yaari, R. , Woodruff, Bryan K. , Hoffman‐Snyder, Charlene , Rademakers, Rosa , Findley, Scott, Reiman, Eric M. , Baxter, Leslie C. , Dueck, A. C. , Locke, Dona E C
Neurology | February 17, 2011 | Volume: 76 | Issue: 12 | Pages: 1078-1084
Medical Management of Frontotemporal Dementia
Caselli, Richard J. , Yaari, R.
American Journal of Alzheimer's Disease & Other Dementias® | December 31, 2007 | Volume: 22 | Issue: 6 | Pages: 489-498
There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.